수술용 메쉬 시장 : 제품 유형, 고정 방법, 원료 유형, 용도, 최종사용자별 - 세계 시장 예측(2026-2032년)

The Surgical Mesh Market is projected to grow by USD 4.79 billion at a CAGR of 8.16% by 2032.

The surgical mesh market is shaped by high procedure volumes in hernia repair, pelvic floor reconstruction, abdominal wall reconstruction, and select soft-tissue reinforcement applications. Global clinical literature consistently identifies hernia repair as one of the most common general surgery procedures, with more than 20 million repairs performed worldwide each year, making durable, biocompatible mesh a core hospital and ambulatory surgery center supply category.

Demand is supported by aging populations, rising obesity and diabetes prevalence, and improved access to minimally invasive surgery. At the same time, purchasing decisions are increasingly influenced by long-term safety evidence, recurrence reduction, infection control, patient-reported outcomes, and regulatory scrutiny surrounding mesh performance.

Transformative Shifts in the Surgical Mesh Landscape

The landscape is moving from commodity polypropylene mesh toward evidence-led product selection, including lightweight, macroporous, composite, biosynthetic, and biologic meshes designed for specific anatomical and contamination-risk profiles. Surgeons are also adopting laparoscopic, robotic, and enhanced recovery pathways that require meshes compatible with precise fixation, reduced adhesions, and shorter hospital stays.

Regulatory and legal history continues to reshape the sector. The U.S. FDA ordered manufacturers to stop selling transvaginal mesh for pelvic organ prolapse in 2019, reinforcing the need for rigorous clinical evidence, transparent labeling, and strong post-market surveillance while preserving mesh use in validated hernia and selected urogynecologic procedures.

Cumulative Impact of Artificial Intelligence on Surgical Mesh

Artificial intelligence is creating measurable value across surgical mesh development, selection, and surveillance. AI-enabled imaging can help quantify hernia defect size, tissue quality, and recurrence risk, while predictive analytics can support patient-specific mesh choice by integrating comorbidities such as obesity, smoking status, diabetes, prior infection, and wound classification.

For manufacturers and providers, AI can improve clinical trial design, adverse-event signal detection, inventory planning, and manufacturing quality control. The strongest near-term impact is expected where AI is paired with validated electronic health record data, unique device identifiers, registries, and robotic surgery platforms rather than used as a stand-alone decision tool.

Key Regional Insights for Surgical Mesh

North America remains a high-value surgical mesh market due to established reimbursement, high hernia procedure volumes, broad use of minimally invasive surgery, and active FDA oversight. The United States and Canada benefit from mature ambulatory surgery infrastructure, electronic health records, device traceability initiatives, and strong adoption of laparoscopic and robotic hernia repair. Europe is driven by sophisticated hospital networks and the EU Medical Device Regulation, which has raised expectations for clinical evidence, post-market follow-up, and vigilance reporting across countries including Germany, France, Italy, Spain, and the United Kingdom.

Asia-Pacific is the fastest-expanding opportunity base as China, India, Japan, South Korea, Australia, and ASEAN countries add surgical capacity, expand insurance coverage, and address large untreated hernia burdens. Latin America shows steady demand in Brazil and Mexico as private hospital networks expand and surgeons increase minimally invasive capability. The Middle East benefits from GCC investment in specialty surgical centers, advanced operating rooms, and medical tourism, while Africa is earlier in adoption but has long-term potential as surgical access improves, particularly where public health systems and international surgical programs strengthen basic infrastructure and affordable mesh supply.

Key Group Insights Across Strategic Markets

Within ASEAN, demand is supported by hospital modernization, medical tourism, and rising laparoscopic capability in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. The GCC is a premium procurement environment where public investment, advanced operating rooms, international accreditation, and specialist surgical programs favor high-quality synthetic, composite, and procedure-specific meshes. The European Union is increasingly evidence-driven because MDR requirements strengthen clinical evaluation, traceability, post-market clinical follow-up, and vigilance obligations for implantable medical devices.

BRICS countries represent large-volume growth, led by China and India for population scale and surgical infrastructure expansion, Brazil for Latin American leadership, and Russia and South Africa for procedure demand shaped by public procurement and access constraints. G7 markets remain innovation centers for robotic surgery, biosynthetic materials, registries, health technology assessment, and reimbursement evidence. NATO-aligned markets benefit from mature hospital supply chains, common quality expectations, and regulatory convergence, which supports faster diffusion of validated surgical mesh technologies when clinical evidence and safety documentation are strong.

Key Country Insights for Surgical Mesh

The United States leads in premium surgical mesh adoption, robotic-assisted hernia repair, ambulatory surgery utilization, and post-market surveillance, while Canada emphasizes evidence-based procurement, patient safety monitoring, and publicly funded care pathways. Mexico and Brazil are important Latin American growth markets, supported by expanding private hospitals, urban surgical capacity, and high hernia repair demand. The United Kingdom, Germany, France, Italy, and Spain combine mature surgical practice with increasing pressure to document outcomes, cost-effectiveness, and compliance with European clinical evidence standards, while Germany and France remain influential in hospital procurement quality expectations.

Russia remains a sizeable procedure market with procurement sensitivity and reliance on cost-effective product availability. China and India provide the largest long-term volume upside because of population scale, improving hospital infrastructure, rising access to elective surgery, and growing surgeon training in minimally invasive repair. Japan, South Korea, and Australia favor high-quality products, minimally invasive techniques, and robust clinical governance, with Japan emphasizing aging-related surgical demand, South Korea demonstrating strong advanced surgical adoption, and Australia maintaining strict safety, reimbursement, and clinical evidence expectations.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence generation through prospective studies, registry participation, and long-term follow-up on recurrence, chronic pain, infection, seroma, adhesion, mesh migration, and explantation outcomes. Product portfolios should be segmented by procedure type, anatomical site, contamination risk, surgical approach, fixation method, and value tier rather than marketed as one-size-fits-all solutions.

Commercial teams should align with hospitals on total cost of care, not only unit price. Recommended actions include strengthening UDI-based traceability, expanding surgeon education, investing in AI-supported post-market surveillance, localizing supply for high-growth regions, improving sterile packaging resilience, and maintaining transparent patient risk communication to rebuild trust in mesh-based procedures.

Research Methodology for Surgical Mesh Market Analysis

This executive summary is built from secondary research using verified public sources, including regulatory communications, clinical guideline themes, peer-reviewed surgical literature, hospital procedure trends, and macroeconomic indicators related to aging, obesity, diabetes, and surgical access. Market interpretation emphasizes documented drivers, clinical evidence, regulatory requirements, and health system readiness rather than unsupported claims.

The methodology evaluates technology trends, regulatory shifts, regional health system maturity, competitive behavior, procurement patterns, and surgical adoption indicators. Insights are triangulated across clinical adoption, safety surveillance, reimbursement context, device traceability, and country-level infrastructure to provide a practical view of the surgical mesh market for strategic planning.

Conclusion: Strategic Outlook for Surgical Mesh

Surgical mesh remains essential to modern hernia and selected reconstructive surgery because it can reduce recurrence when appropriately selected and implanted. The market is advancing toward procedure-specific materials, higher clinical evidence standards, better traceability, and more data-driven decision-making across hospitals, ambulatory surgery centers, and specialist surgical programs.

Future progress will favor organizations that combine proven safety, surgeon usability, regulatory discipline, reliable supply, and measurable economic value. As AI, robotics, registries, and material science converge, the strongest market participants will be those that deliver durable outcomes while addressing patient safety, regulatory confidence, and hospital cost pressures.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Surgical Mesh Market, by Product Type

• 7.1. Absorbable Mesh
  • 7.1.1. Polyglactin Mesh
  • 7.1.2. Polyglycolic Mesh
• 7.2. Non-Absorbable Mesh
  • 7.2.1. Expanded Polytetrafluoroethylene Mesh
  • 7.2.2. Polyester Mesh
  • 7.2.3. Polypropylene Mesh

8. Surgical Mesh Market, by Fixation Technique

• 8.1. Adhesive-Based Fixation
  • 8.1.1. Biological Adhesives
  • 8.1.2. Synthetic Adhesives
• 8.2. Suture-Based Fixation
  • 8.2.1. Continuous Sutures
  • 8.2.2. Interrupted Sutures
• 8.3. Tack-Based Fixation
  • 8.3.1. Absorbable Tacks
  • 8.3.2. Non-Absorbable Tacks

9. Surgical Mesh Market, by Source Type

• 9.1. Biological
• 9.2. Synthetic

10. Surgical Mesh Market, by Application

• 10.1. Breast Reconstruction
• 10.2. Hernia Repair
• 10.3. Pelvic Organ Prolapse
• 10.4. Reconstructive Surgery
• 10.5. Stress Urinary Incontinence
• 10.6. Traumatic/Surgical Wounds

11. Surgical Mesh Market, by End User

• 11.1. Ambulatory Surgical Centers
• 11.2. Clinics
• 11.3. Hospitals

12. Surgical Mesh Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Surgical Mesh Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Surgical Mesh Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. 3M Company
• 16.2. Angiologica B.M. S.r.l.
• 16.3. Aran Biomedical
• 16.4. ASSUT Europe S.p.A.
• 16.5. B. Braun Melsungen AG
• 16.6. Becton, Dickinson and Company
• 16.7. Betatech Medical
• 16.8. BG Medical LLC
• 16.9. BioCer Entwicklungs-GmbH
• 16.10. Boston Scientific Corporation
• 16.11. Coloplast Corp.
• 16.12. Cousin Biotech SAS
• 16.13. Deep Blue Medical Advances, Inc.
• 16.14. Dipromed Srl
• 16.15. Dolphin Sutures
• 16.16. Integra LifeSciences Corporation
• 16.17. Johnson & Johnson Services, Inc
• 16.18. KLS Martin Group
• 16.19. Lotus Surgicals
• 16.20. Medtronic PLC
• 16.21. Novus Scientific AB
• 16.22. Tela Bio, Inc.
• 16.23. THT Bio-Science
• 16.24. Vitrex Medical A/S
• 16.25. W. L. Gore & Associates, Inc.